IFI27 and systemic lupus erythematosus: Overall, our results indicate that targeting IFI27 might reduce the molecules that mediate immmune infection, suggesting that the potential value of combining blockades of IFI27 and coinhibitory molecules may serve as a new immunotherapy against SLE.